PCA patients: demographics and clinical-technical investigations
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Case 8 | Case 9 | Case 10 | Case 11 | Case 12 | Case 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | 68 | 67 | 56 | 63 | 52 | 51 | 57 | 65 | 54 | 61 | 71 | 53 | 66 |
| Sex | F | M | M | F | F | F | F | F | F | M | F | F | F |
| Disease duration (y) | 1.5 | 2 | 1 | 1.5 | 1.5 | 2 | 1 | 0.75 | 0.5 | 0.5 | 2 | 3.75 | 3 |
| MMSE | 27 | 28 | 22 | 26 | 19 | 24 | 19 | 17 | 20 | 21 | 26 | 22 | 23 |
| Measures of topography | |||||||||||||
| Structural MRI | + | + | + | + | + | + | + | + | + | + | + | + | + |
| FDG-PET | + | + | + | + | − | + | + | + | + | + | + | − | + |
| Amyloid biomarkers | |||||||||||||
| PIB PET SUVRcomp (cutoff = 1.43) | 2.17 | − | − | − | 1.92 | − | 2.20 | − | − | − | − | − | − |
| CSF Aβ42 (pg/ml) (cutoff = 600 pg/ml) | 312 | 337 | 389 | − | 581 | 239 | − | − | − | − | − | 359 | 457 |
SUVRcomp, Standardized uptake value ratio in the composite cortical volume of interest; −, test not performed.